Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M. Duruisseaux M, et al. Among authors: perez l. Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9. Lancet Respir Med. 2018. PMID: 30100403 Free article.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Gálvez F, Falcón A, Alamo MDC, Morales C, Amerigo M, Pascual J, Sanchez-Muñoz A, González-Guerrero M, Vicioso L, Laborda A, Ortega MV, Perez L, Fernandez-Martinez A, Chic N, Jerez JM, Alvarez M, Prat A, Ribelles N, Alba E. Díaz-Redondo T, et al. Among authors: perez l. Front Oncol. 2019 Nov 5;9:1178. doi: 10.3389/fonc.2019.01178. eCollection 2019. Front Oncol. 2019. PMID: 31750258 Free PMC article.
Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer.
Pérez-Ruiz E, Rueda A, Pérez L, Rivas-Ruiz F, Torres E, de Luque V, Álvarez M, Sevilla I, Redondo M, Padilla-Ruiz M, Alba E, Alonso L. Pérez-Ruiz E, et al. Among authors: perez l. Pathol Oncol Res. 2018 Oct;24(4):871-879. doi: 10.1007/s12253-017-0301-8. Epub 2017 Sep 9. Pathol Oncol Res. 2018. PMID: 28889324 Free article.
Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation.
Pérez-Ruiz E, Cazorla O, Redondo M, Pérez L, Álvarez M, Gallego E, Trigo JM, Medina JA, Matilla A, Rueda A. Pérez-Ruiz E, et al. Among authors: perez l. Clin Transl Oncol. 2012 Sep;14(9):682-8. doi: 10.1007/s12094-012-0859-2. Epub 2012 Jul 24. Clin Transl Oncol. 2012. PMID: 22855152
ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.
Zamora I, Gutiérrez M, Pascual A, Pajares MJ, Barajas M, Perez LM, You S, Knudsen BS, Freeman MR, Encío IJ, Rotinen M. Zamora I, et al. Among authors: perez lm. Cell Oncol (Dordr). 2024 May 31. doi: 10.1007/s13402-024-00957-3. Online ahead of print. Cell Oncol (Dordr). 2024. PMID: 38819630
2,125 results